Home >> Healthcare Administration >> Pharmaceuticals >> Food & Beverage >>

Candidiasis - Pipeline Review, H2 2013

Published: Sep-2013 | Format: PDF | Global Markets Direct | Number of pages: 81 | Code: MRS - 993

Global Markets Directs, 'Candidiasis Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Candidiasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Candidiasis. Candidiasis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Scope

A snapshot of the global therapeutic scenario for Candidiasis.
A review of the Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Candidiasis pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Candidiasis.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Candidiasis Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Candidiasis 10
Candidiasis Therapeutics under Development by Companies 12
Candidiasis Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Candidiasis Therapeutics - Products under Development by Companies 19
Candidiasis Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Candidiasis Therapeutics Development 21
Daiichi Sankyo Company, Ltd 21
Merck & Co., Inc. 22
Novartis AG 23
iCo Therapeutics Inc. 24
Almirall, S.A. 25
Basilea Pharmaceutica Ltd. 26
Pacgen Biopharmaceuticals Corporation 27
NovaDigm Therapeutics, Inc. 28
Ancora Pharmaceuticals Inc. 29
Viamet Pharmaceuticals, Inc. 30
Aparna Biosciences Corp. 31
Aureogen Biosciences, Inc. 32
Candidiasis - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
isavuconazole - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
PAC-113 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
posaconazole - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
LAS-41003 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
amphotericin B - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
NDV-3 Vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SLP-1002 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
SLP-0907 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SLP-0901 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
VT-1161 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
D11-2040 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Xenomycin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Vaccine For Candida - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AUGC-15 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Antifungal Compounds - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Drug For Candiasis - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Compound-18545 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Compound-9403 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Compound-14844 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Candida Vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Chlorogenic Acid Based Peptidomimetic - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
AB-174 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
FWB-016-A001 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
FWB-017-A001 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
FWB-018-A001 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Drug For Fungal Infections - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Candidiasis Therapeutics - Drug Profile Updates 68
Candidiasis Therapeutics - Discontinued Products 71
Candidiasis Therapeutics - Dormant Products 72
Candidiasis - Product Development Milestones 73
Featured News & Press Releases 73
Jul 17, 2013: Basilea provides update on isavuconazole phase 3 program 73
Jun 24, 2013: FDA Approves Pediatric Indication For Astellas's Mycamine For Injection 73
Apr 29, 2013: Basilea Pharma Presents Data On Anti-fungal Drug Candidate Isavuconazole At ECCMID 2013 74
Apr 10, 2013: Merck Announces FDA Acceptance Of NDA For Investigational Tablet Formulation Of Antifungal Noxafil 75
Dec 13, 2012: NovaDigm Announce Publication Of Positive Phase I Study Data Of NDV-3 Vaccine For Candida And Staph Infections In Vaccine Journal 75
Jun 21, 2012: Mayne Pharma Receives MHRA Approval For Subacap 76
May 07, 2012: NovaDigm Therapeutics Presents Positive Safety And Immunogenicity Data In Second Phase I Study For NDV-3 Vaccine 77
Dec 15, 2011: Mayne Pharma Provides Update On Subacap European Marketing Approval Application 78
Sep 19, 2011: NovaDigm Presents Positive Phase I Safety And Immunogenicity Data For NDV-3 Vaccine 78
Sep 12, 2011: NovaDigm Therapeutics To Present Positive Phase I Clinical Data For NDV-3 Vaccine At ICAAC 79

Appendix 80

Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81

List of Tables

Number of Products Under Development for Candidiasis, H2 2013 10
Products under Development for Candidiasis - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Clinical Stage Development, H2 2013 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 18
Products under Development by Companies, H2 2013 19
Products under Investigation by Universities/Institutes, H2 2013 20
Daiichi Sankyo Company, Ltd, H2 2013 21
Merck & Co., Inc., H2 2013 22
Novartis AG, H2 2013 23
iCo Therapeutics Inc., H2 2013 24
Almirall, S.A., H2 2013 25
Basilea Pharmaceutica Ltd., H2 2013 26
Pacgen Biopharmaceuticals Corporation, H2 2013 27
NovaDigm Therapeutics, Inc., H2 2013 28
Ancora Pharmaceuticals Inc., H2 2013 29
Viamet Pharmaceuticals, Inc., H2 2013 30
Aparna Biosciences Corp., H2 2013 31
Aureogen Biosciences, Inc., H2 2013 32
Assessment by Monotherapy Products, H2 2013 33
Assessment by Stage and Route of Administration, H2 2013 35
Assessment by Stage and Molecule Type, H2 2013 37
Candidiasis Therapeutics - Drug Profile Updates 68
Candidiasis Therapeutics - Discontinued Products 71
Candidiasis Therapeutics - Dormant Products 72 
List of Figures

Number of Products under Development for Candidiasis, H2 2013 10
Products under Development for Candidiasis - Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 14
Late Stage Products, H2 2013 15
Mid Clinical Stage Products, H2 2013 16
Early Clinical Stage Products, H2 2013 17
Discovery and Pre-Clinical Stage Products, H2 2013 18
Assessment by Monotherapy Products, H2 2013 33
Assessment by Route of Administration, H2 2013 34
Assessment by Stage and Route of Administration, H2 2013 35
Assessment by Molecule Type, H2 2013 36
Assessment by Stage and Molecule Type, H2 2013 37

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing